Moderna stock took a sharp hit on July 10, 2026, falling 10.7% — a drop of $8.17 — to close at $68.39. The move adds to a broader pattern of pressure on the biotech.
The stock opened that day at $76.56. Moderna’s 52-week range runs from $22.28 to $85.60, so the current price sits in the upper half of that band — but the recent slide suggests the air up there is getting thin.
The most recent earnings report, released May 1, didn’t do the stock any favors. Moderna posted a loss of $3.40 per share, worse than the -$3.02 analysts had expected. That’s a miss, and the market tends to remember those.
Revenue was a different story. The company brought in $389 million for the quarter, blowing past the $236.37 million consensus estimate. That’s a 260.2% jump compared to the same period last year.
Still, a revenue beat can only go so far when profitability remains elusive. Moderna carries a negative net margin of 143.55% and a negative return on equity of 26.64%.
Insiders have been heading for the exit. Over the past three months, they sold $6.2 million worth of stock — and bought none.
Director Noubar Afeyan sold 9,263 shares on May 21 at an average price of $46.84, cutting his position by 70.24%. President Stephen Hoge sold 53,336 shares on June 15 at $51.37 per share, a transaction totaling roughly $2.74 million.
Those sales were made under pre-arranged 10b5-1 plans, which are scheduled in advance. But the sheer volume of selling tends to catch investor attention.
Insiders collectively own 10.80% of the stock. Institutional investors hold 75.33%.
Analyst sentiment isn’t exactly a ringing endorsement right now. Of the 18 analysts covering Moderna, two rate it a Buy, eleven say Hold, and five say Sell. The average rating works out to “Reduce.”
The consensus price target sits at $38.27 — well below where the stock is currently trading.
Morgan Stanley recently raised its price target from $33 to $39 with an “equal weight” rating. Goldman Sachs moved its target from $43 to $49 with a “neutral.” Bank of America bumped its target from $34 to $38 but kept an “underperform” rating.
Weiss Ratings maintained a “sell (d-)” on June 12.
On the institutional side, QRG Capital Management opened a new position in Q1, picking up 13,666 shares worth about $694,000. A handful of other smaller funds also added positions, though the amounts were modest.
Moderna’s GF Score stands at 58 out of 100. Financial Strength rates 7/10, Growth 7/10, but Profitability comes in at just 3/10.
The 50-day moving average is $55.75. The 200-day moving average is $49.53. Sell-side analysts as a group expect Moderna to post -$6.51 EPS for the full year.
The post Moderna (MRNA) Stock Falls 11% as Insiders Sell and Analysts Stay Cautious appeared first on CoinCentral.
